Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Relay Therapeutics Inc (NASDAQ: RLAY) closed at $8.65 in the last session, up 4.09% from day before closing price of $8.31. In other words, the price has increased by $4.09 from its previous closing price. On the day, 0.87 million shares were traded. RLAY stock price reached its highest trading level at $8.76 during the session, while it also had its lowest trading level at $8.34.
Ratios:
We take a closer look at RLAY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.Wells Fargo initiated its Equal Weight rating on April 17, 2025, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1499238528 and an Enterprise Value of 936136640. For the stock, the TTM Price-to-Sale (P/S) ratio is 179.33 while its Price-to-Book (P/B) ratio in mrq is 2.46. Its current Enterprise Value per Revenue stands at 112.045 whereas that against EBITDA is -2.921.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.56, which has changed by 0.983945 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $9.04, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 18.89%, while the 200-Day Moving Average is calculated to be 93.12%.
Shares Statistics:
According to the various share statistics, RLAY traded on average about 2.18M shares per day over the past 3-months and 2735000 shares per day over the past 10 days. A total of 172.63M shares are outstanding, with a floating share count of 130.41M. Insiders hold about 24.76% of the company’s shares, while institutions hold 74.71% stake in the company. Shares short for RLAY as of 1765756800 were 20296216 with a Short Ratio of 9.32, compared to 1763078400 on 21371170. Therefore, it implies a Short% of Shares Outstanding of 20296216 and a Short% of Float of 14.19.
Earnings Estimates
Relay Therapeutics Inc (RLAY) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.41 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.5 and -$2.08 for the fiscal current year, implying an average EPS of -$1.74. EPS for the following year is -$1.61, with 6.0 analysts recommending between -$1.41 and -$1.78.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8M, resulting in an average revenue estimate of $12.77M. In the same quarter a year ago, actual revenue was $10.01M
